These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1204 related items for PubMed ID: 30215174

  • 21. Head-to-Head Comparison of 68Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10-Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer Patients.
    Schilham MGM, Zamecnik P, Privé BM, Israël B, Rijpkema M, Scheenen T, Barentsz JO, Nagarajah J, Gotthardt M.
    J Nucl Med; 2021 Sep 01; 62(9):1258-1263. PubMed ID: 33517328
    [Abstract] [Full Text] [Related]

  • 22. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study.
    Lenis AT, Pooli A, Lec PM, Sadun TY, Johnson DC, Lebacle C, Fendler WP, Eiber M, Czernin J, Reiter RE, Calais J.
    Eur Urol Oncol; 2022 Oct 01; 5(5):544-552. PubMed ID: 32958451
    [Abstract] [Full Text] [Related]

  • 23. Comparison of 68Ga-PSMA-11 PET-CT with mpMRI for preoperative lymph node staging in patients with intermediate to high-risk prostate cancer.
    Zhang Q, Zang S, Zhang C, Fu Y, Lv X, Zhang Q, Deng Y, Zhang C, Luo R, Zhao X, Wang W, Wang F, Guo H.
    J Transl Med; 2017 Nov 07; 15(1):230. PubMed ID: 29115970
    [Abstract] [Full Text] [Related]

  • 24. 68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer.
    Herlemann A, Wenter V, Kretschmer A, Thierfelder KM, Bartenstein P, Faber C, Gildehaus FJ, Stief CG, Gratzke C, Fendler WP.
    Eur Urol; 2016 Oct 07; 70(4):553-557. PubMed ID: 26810345
    [Abstract] [Full Text] [Related]

  • 25. 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour.
    Uprimny C, Kroiss AS, Decristoforo C, Fritz J, von Guggenberg E, Kendler D, Scarpa L, di Santo G, Roig LG, Maffey-Steffan J, Horninger W, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2017 Jun 07; 44(6):941-949. PubMed ID: 28138747
    [Abstract] [Full Text] [Related]

  • 26. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer.
    Sanli Y, Kuyumcu S, Sanli O, Buyukkaya F, İribaş A, Alcin G, Darendeliler E, Ozluk Y, Yildiz SO, Turkmen C.
    Ann Nucl Med; 2017 Nov 07; 31(9):709-717. PubMed ID: 28900854
    [Abstract] [Full Text] [Related]

  • 27. Prospective comparison of whole-body MRI and 68Ga-PSMA PET/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy.
    Sawicki LM, Kirchner J, Buddensieck C, Antke C, Ullrich T, Schimmöller L, Boos J, Schleich C, Schaarschmidt BM, Buchbender C, Heusch P, Rabenalt R, Albers P, Antoch G, Müller HW, Hautzel H.
    Eur J Nucl Med Mol Imaging; 2019 Jul 07; 46(7):1542-1550. PubMed ID: 30879122
    [Abstract] [Full Text] [Related]

  • 28. Impact of uptake time on image quality of [68 Ga]Ga-PSMA-11 PET/CT.
    van der Sar ECA, Viol SLM, Braat AJAT, van Rooij R, Lam MGEH, de Jong HWAM, de Keizer B.
    Med Phys; 2023 Dec 07; 50(12):7619-7628. PubMed ID: 37093883
    [Abstract] [Full Text] [Related]

  • 29. Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for staging of high-risk prostate cancer68Ga-PSMA PET and MRI in prostate cancer.
    Tulsyan S, Das CJ, Tripathi M, Seth A, Kumar R, Bal C.
    Nucl Med Commun; 2017 Dec 07; 38(12):1094-1102. PubMed ID: 28957842
    [Abstract] [Full Text] [Related]

  • 30. Is there a utility of adding skeletal imaging to 68-Ga-prostate-specific membrane antigen-PET/computed tomography in initial staging of patients with high-risk prostate cancer?
    Raju S, Sharma A, Patel C, Sahoo R, Das CJ, Kumar S, Sharma A, Kumar R.
    Nucl Med Commun; 2020 Nov 07; 41(11):1183-1188. PubMed ID: 32796451
    [Abstract] [Full Text] [Related]

  • 31. Comparison of preoperative locoregional Ga-68 PSMA-11 PET-CT and mp-MRI results with postoperative histopathology of prostate cancer.
    Yilmaz B, Turkay R, Colakoglu Y, Baytekin HF, Ergul N, Sahin S, Tugcu V, Inci E, Tasci AI, Cermik TF.
    Prostate; 2019 Jun 07; 79(9):1007-1017. PubMed ID: 31012125
    [Abstract] [Full Text] [Related]

  • 32. Unexpected significant findings non-related to prostate cancer identified using combined prostate-specific membrane antigen positron emission tomography/CT and diagnostic CT scan in primary staging for prostate cancer.
    McEwan L, McBean R, Yaxley J, Wong D.
    J Med Imaging Radiat Oncol; 2019 Jun 07; 63(3):318-323. PubMed ID: 30840361
    [Abstract] [Full Text] [Related]

  • 33. The management impact of 68gallium-tris(hydroxypyridinone) prostate-specific membrane antigen (68Ga-THP-PSMA) PET-CT imaging for high-risk and biochemically recurrent prostate cancer.
    Kulkarni M, Hughes S, Mallia A, Gibson V, Young J, Aggarwal A, Morris S, Challacombe B, Popert R, Brown C, Cathcart P, Dasgupta P, Warbey VS, Cook GJR.
    Eur J Nucl Med Mol Imaging; 2020 Mar 07; 47(3):674-686. PubMed ID: 31872280
    [Abstract] [Full Text] [Related]

  • 34. Hybrid imaging with [68Ga]PSMA-11 PET-CT and PET-MRI in biochemically recurrent prostate cancer.
    Glemser PA, Rotkopf LT, Ziener CH, Beuthien-Baumann B, Weru V, Kopp-Schneider A, Schlemmer HP, Dimitrakopoulou-Strauss A, Sachpekidis C.
    Cancer Imaging; 2022 Sep 22; 22(1):53. PubMed ID: 36138437
    [Abstract] [Full Text] [Related]

  • 35. Five-year trends of bone scan and prostate-specific membrane antigen positron emission tomography utilization in prostate cancer: A retrospective review in a private centre.
    Haran C, McBean R, Parsons R, Wong D.
    J Med Imaging Radiat Oncol; 2019 Aug 22; 63(4):495-499. PubMed ID: 30972933
    [Abstract] [Full Text] [Related]

  • 36. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment.
    van Leeuwen PJ, Stricker P, Hruby G, Kneebone A, Ting F, Thompson B, Nguyen Q, Ho B, Emmett L.
    BJU Int; 2016 May 22; 117(5):732-9. PubMed ID: 26683282
    [Abstract] [Full Text] [Related]

  • 37. Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT.
    Schwenck J, Rempp H, Reischl G, Kruck S, Stenzl A, Nikolaou K, Pfannenberg C, la Fougère C.
    Eur J Nucl Med Mol Imaging; 2017 Jan 22; 44(1):92-101. PubMed ID: 27557844
    [Abstract] [Full Text] [Related]

  • 38. 68Ga-PSMA PET/CT for Primary Lymph Node and Distant Metastasis NM Staging of High-Risk Prostate Cancer.
    Klingenberg S, Jochumsen MR, Ulhøi BP, Fredsøe J, Sørensen KD, Borre M, Bouchelouche K.
    J Nucl Med; 2021 Feb 22; 62(2):214-220. PubMed ID: 32444374
    [Abstract] [Full Text] [Related]

  • 39. Clinical parameters and nomograms for predicting lymph node metastasis detected with 68 Ga-PSMA-PET/CT in prostate cancer patients candidate to definitive radiotherapy.
    Onal C, Ozyigit G, Oymak E, Guler OC, Hurmuz P, Tilki B, Reyhan M, Tuncel M, Akyol F.
    Prostate; 2021 Jul 22; 81(10):648-656. PubMed ID: 33949694
    [Abstract] [Full Text] [Related]

  • 40. Head-to-head comparisons of [68Ga]Ga-PSMA-11 PET/CT, multiparametric MRI, and prostate-specific antigen for the evaluation of therapeutic responses to neoadjuvant chemohormonal therapy in high-risk non-metastatic prostate cancer patients: a prospective study.
    Ke ZB, Chen SM, Chen JY, Chen SH, You Q, Sun JB, Xue YT, Sun XL, Wu XH, Zheng QS, Wei Y, Xue XY, Xu N.
    Eur J Nucl Med Mol Imaging; 2023 Mar 22; 50(4):1240-1251. PubMed ID: 36416906
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 61.